Gilead Sciences, Inc. $GILD Shares Sold by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 109,831 shares of the biopharmaceutical company’s stock after selling 29,409 shares during the period. Texas Permanent School Fund Corp’s holdings in Gilead Sciences were worth $12,177,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Activest Wealth Management grew its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the second quarter worth approximately $27,000. Putney Financial Group LLC raised its holdings in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,806 shares of the firm’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $127.11, for a total transaction of $356,670.66. Following the transaction, the director directly owned 1,339 shares in the company, valued at $170,200.29. This trade represents a 67.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00. Following the sale, the chief executive officer owned 571,203 shares of the company’s stock, valued at approximately $72,280,027.62. This trade represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 130,257 shares of company stock worth $15,991,492 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $120.40 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The stock’s 50-day moving average is $121.89 and its two-hundred day moving average is $115.81. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market cap of $149.38 billion, a P/E ratio of 18.67, a PEG ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the company earned $2.02 EPS. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 48.99%.

Analyst Ratings Changes

Several analysts have issued reports on GILD shares. Scotiabank assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Daiwa Capital Markets upped their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Wolfe Research reiterated an “outperform” rating on shares of Gilead Sciences in a report on Monday. Finally, Morgan Stanley increased their price target on shares of Gilead Sciences from $147.00 to $151.00 and gave the stock an “overweight” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $131.13.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.